Clinical trials: Head and Neck Squamous Cell Carcinomas
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC)
Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer
Avmacol is an over-the-counter dietary supplement containing broccoli seed and sprout extracts in tablet form, hypothesized to activate protective cellular pathways including detoxication.
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Head and Neck Carcinoma, Head and Neck
- Trial name
- NCT03268993
- Testing
- Avmacol
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- University of Pittsburgh
Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer
Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCC
VERSATILE-002 is a Phase 2, open-label, multicenter study of the efficacy and safety of PDS0101 administered in combination with pembrolizumab in adults with HPV16 and PD-L1 positive recurrent or metastatic head and neck squamous…
- Conditions
- Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Neoplasms, Head and Neck
- Trial name
- VERSATILE002 (NCT04260126)
- Testing
- Pembrolizumab (KEYTRUDA®) and PDS0101
- Where
- 23 sites in United States, Ireland and 2 more
- Volunteers
- 95 people
- Sponsor
- PDS Biotechnology Corp.
Esophageal Cancer
dCRT vs. Surgery in Resectable ESCC Patients Achieving cCR/PR After Induction Chemoimmunotherapy
This study is evaluating two treatment approaches for patients with locally advanced, resectable esophageal squamous cell carcinoma (ESCC) who have a good response to 2-3 cycles of induction chemoimmunotherapy.
- Trial name
- SORT (NCT07162506)
- Testing
- Surgery, Radiotherapy, Chemotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Squamous Cell Carcinoma
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
The goal of this clinical research study is to learn which chemotherapy combination may be more effective in treating locally advanced head and neck squamous cell carcinoma (HNSCC).
- Trial name
- NCT02128906
- Testing
- Cisplatin, IMRT, Docetaxel
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Christopher Wilke
Oral Cancer
The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma
Investigate the role of SDF-1/CXCR4 in the metastasis of oral squamous cell carcinoma
- Trial name
- NCT00173849
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Head and Neck Squamous Cell Carcinoma
Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II Study
This is a prospective, single-arm, multi-center, Phase II clinical trial evaluating the efficacy and safety of neoadjuvant becotatug vedotin (an anti-EGFR antibody-drug conjugate) combined with pucotenlimab (HX008, an anti-PD-1…
- Trial name
- GATEWAY (NCT07589049)
- Testing
- Becotatug Vedotin, Pucotenlimab
- Where
- 12 sites in China
- Volunteers
- 42 people
- Sponsor
- Sun Yat-sen University
Laryngeal Carcinoma, Hypopharyngeal Carcinoma
Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma
Neoadjuvant chemotherapy combined with immunotherapy has achieved promising pathological remission rates in locally advanced head and neck squamous cell carcinoma and has offered new hope for patients with locally advanced…
- Trial name
- NCT06957938
- Testing
- Neoadjuvant Chemotherapy (NACT), Neoadjuvant and maintenance Tislelizumab, Concurrent chemo-radiotherapy (CCRT)
- Where
- China
- Volunteers
- 168 people
- Sponsor
- Fudan University
Advanced Solid Tumors, Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Study of INCA 0186 in Subjects With Advanced Solid Tumors
This is an open-label, nonrandomized, multicenter, dose escalation, and dose expansion first-in human (FIH) Phase 1 study to determine the safety, tolerability, PK, pharmacodynamics, and preliminary efficacy of INCA00186 when…
- Conditions
- Advanced Solid Tumors, Squamous Cell Carcinoma of the Head and Neck (SCCHN), Gastrointestinal (GI) Malignancies
- Trial name
- NCT04989387
- Testing
- INCA00186, Retifanlimab, INCB106385
- Where
- 32 sites in United States, Austria and 4 more
- Volunteers
- 57 people
- Sponsor
- Incyte Corporation
Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer
This is a Phase II treatment, non-randomized, open label clinical trial to study the efficacy of the Cetuximab when administered as single agent in recurrent/ metastatic head and neck squamous cell carcinoma after the failure or…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma
- Trial name
- NCT04375384
- Testing
- Cetuximab, Questionnaire administration, Quality of life assessment
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Wake Forest University Health Sciences
Head and Neck Cancer
Molecular Imaging-based Dose Escalation in HPV Negative Patients With Locally Advanced SCC of the Oropharynx
Phase I study to assess the feasibility (i.e. early toxicity) of Molecular Imaging-based Dose Escalation in HPV Negative Patients With Locally Advanced SCC of the Oropharynx.
- Trial name
- NCT02336711
- Testing
- dose escalation
- Where
- 2 sites in Belgium
- Volunteers
- 10 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Head and Neck Squamous Cell Carcinoma
Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Randomized phase II study of immune stimulation with Pembrolizumab and radiotherapy in second line therapy of metastatic head and neck squamous cell carcinoma.
- Trial name
- NCT03386357
- Testing
- A (pembrolizumab+RT), B (pembrolizumab)
- Where
- 7 sites in Germany
- Volunteers
- 115 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Esophageal Squamous Cell Carcinoma, Chemoradiotherapy
Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs for Local Advanced Patients With Inoperable Esophageal Squamous Cell Carcinoma
Chemoradiotherapy has been a standard modality for inoperable locally advance esophageal carcinoma. The goal of this randomized control study is to compare the feasibility, and survival benefits of whole-course immunonutrition…
- Conditions
- Esophageal Squamous Cell Carcinoma, Chemoradiotherapy, Immunonutrition, Inoperable
- Trial name
- NCT05833594
- Testing
- Whole-course Immunonutrition Combined With Chemoradiotherapy±ICIs
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Anhui Provincial Hospital
Cancer, Neoplasms
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
This study will investigate OC-001 as monotherapy, and in combination with, Avelumab, in various cancer types
- Conditions
- Cancer, Neoplasms, Metastatic Cancer, Triple Negative Breast Cancer
- Trial name
- NCT04260802
- Testing
- OC-001, Drug: OC-001 in Combination with Avelumab
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Ocellaris Pharma, Inc.
Metastatic Solid Tumor, Advanced Solid Tumor
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
The main purpose of this study is to evaluate the safety and preliminary efficacy of CHS-114 in combination with toripalimab and/or other standard of care (SOC) compound(s) in participants with advanced or metastatic solid tumors.
- Trial name
- NCT06657144
- Testing
- CHS-114, Toripalimab, 5 Fluorouracil
- Where
- 30 sites in United States, Taiwan
- Volunteers
- 154 people
- Sponsor
- Coherus Oncology, Inc.
Oral Cancer
Epstein-Barr Detection in Oral Cancer
The aim of this study is to analyze oral squamous cell carcinoma and healthy oral mucosa for the possible presence of Epstein-Barr virus (EBV).
- Trial name
- NCT01039272
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- UPECLIN HC FM Botucatu Unesp
Oral Cancer , Oral Squamous Cell Carcinoma, Oral Cavity Cancer
Immunohistochemical Expression of EGFR in the Patients Having Oral Squamous Cell Carcinoma
Oral squamous cell carcinoma (OSCC) is one of the top 10 most common malignancies worldwide. Oral squamous cell carcinoma forms a major health problem in many countries.
- Trial name
- EGFR (NCT06606301)
- Testing
- BioSB EGFR antibody
- Where
- Pakistan
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Combined Military Hospital, Pakistan
Cancer of Head and Neck
Soy Isoflavone in Combination With Radiation Therapy and Cisplatin in SCC of the Head and Neck
The purpose of this study is to determine if soy supplementation during chemotherapy and radiation therapy will decrease side effects caused by treatment.
- Trial name
- NCT02075112
- Testing
- Soy isoflavone, Radiation, Cisplatin
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Emory University
Renal Cell Carcinoma, Melanoma
Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
In this study, the Phase Ib portion aims to establish safety and tolerability of ARRY-614 with either nivolumab or ipilimumab and to determine a recommended phase II dose of ARRY-614 in combination with either nivolumab or…
- Conditions
- Renal Cell Carcinoma, Melanoma, Solid Tumor, Non-small Cell Lung Cancer
- Trial name
- NCT04074967
- Testing
- Phase Ib ARRY-614 + nivolumab, Phase Ib ARRY-614 + nivolumab+ipilimumab, Phase II ARRY-614 + nivolumab
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Dan Zandberg
Esophageal Squamous Cell Carcinomas, Concurrent Chemoradiotherapy
Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)
This is an investigator-initiated, single-arm, exploratory clinical study.The study population consisted of non-operative Locally Advanced Esophageal Cancer .
- Conditions
- Esophageal Squamous Cell Carcinomas, Concurrent Chemoradiotherapy, Immunotherapy, Chemotherapy
- Trial name
- RICE (NCT05621707)
- Testing
- chemotherapy combined with PD-1 inhibitors
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai Chest Hospital
Carcinoma, Squamous Cell, Carcinoma, Squamous Cell of Head and Neck
Super-Selective Intraarterial Infusion of Cetuximab (Erbitux) With or Without Radiation Therapy for the Treatment of Unresectable Recurrent Squamous Cell Carcinoma of the Head and Neck
This is an open-label, non-randomized, two arm, Phase I research study of superselective intraarterial Cetuximab (Erbitux) with or without radiation therapy for treatment of recurrent unresectable squamous cell carcinoma of the…
- Trial name
- NCT02438995
- Testing
- Intraarterial Cetxuimab (Erbitux)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Northwell Health
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.